Wells Fargo has recently downgraded its investment rating for cell therapy company ARCELLX, INC. from "Overweight" to "Equal Weight".

Analyst: DeepSeek's new AI model, if competitive, could cause turbulence for Nasdaq AI-related stocks

Keurig Dr Pepper Inc (KDP) Chief Financial Officer recently revealed that the company expects first-quarter earnings per share (EPS) to fluctuate between $0.36 and $0.37.

In the current capital market environment, Empery Digital Inc., with its robust financial structure, has clearly stated that the company possesses ample cash reserves sufficient to support the implementation of its share repurchase plan.

Cadrenal Therapeutics Inc recently received approval from the U.S. Food and Drug Administration (FDA) to hold an end-of-Phase II clinical trial meeting.